Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Oct 2, 2026

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55th Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada, from October 14 – 17, 2026. The presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting.

GlobeNewsWire • Oct 1, 2026

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivotal data collection and manufacturing scale-up without immediate dependence on accelerated regulatory filing. TSHA-102's early data show deepening, durable functional gains in Rett patients, but pivotal efficacy, safety, and manufacturing qualification remain key investment inflection points.

Seeking Alpha • Sep 11, 2026

These 3 Risky Stocks Could Be Sitting on 100% Upside

With industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While it's true that some long-established firms have posted surprising rallies in recent trading sessions, a combination of consumer reticence and stretched valuations means that many go-to investments may not see much near-term growth.

MarketBeat • Sep 7, 2026

Taysha Gene Therapies Q2 Earnings Call Highlights

Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.

MarketBeat • Aug 12, 2026

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

GlobeNewsWire • Aug 11, 2026

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time.

GlobeNewsWire • Aug 4, 2026

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla.

GlobeNewsWire • Aug 3, 2026

Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential

Taysha Gene Therapies (TSHA) remains a "Buy," driven by strong TSHA-102 data in Rett Syndrome and pivotal trial progress. TSHA-102 achieved 100% response rate at 12 months in Part A, surpassing the 33% response threshold needed for regulatory submission. Alignment with the FDA on pivotal trial endpoints and interim analysis could enable an accelerated BLA submission in 1H 2027.

Seeking Alpha • Jun 30, 2026